Alterity Therapeutics Limited (PRNAF)
OTCMKTS · Delayed Price · Currency is USD
0.0097
-0.0011 (-10.19%)
At close: Jan 22, 2026
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M AUD with 35.32% growth. Alterity Therapeutics had revenue of 3.83M in the half year ending June 30, 2025, with 150.44% growth.
Revenue
5.44M AUD
Revenue Growth
+35.32%
P/S Ratio
17.31
Revenue / Employee
604.32K AUD
Employees
9
Market Cap
61.71M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Nuo Therapeutics | 2.61M |
| Harvard Apparatus Regenerative Technology | 743.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Alterity Therapeutics News
- 13 days ago - Alterity Therapeutics (ATHE) Advances Phase 3 Program with Strong Financials - GuruFocus
- 13 days ago - Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 22 days ago - Alterity Therapeutics (ATHE) Advances towards Phase 3 Trials with Promising MSA Treatment - GuruFocus
- 3 months ago - Alterity Therapeutics (ATHE) Pioneers Unique Approach to Neurodegeneration - GuruFocus
- 3 months ago - Alterity Therapeutics (ATHE) Focuses on Parkinson's Disease Research - GuruFocus
- 3 months ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire
- 3 months ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 4 months ago - Alterity Therapeutics (ATHE) Unveils Promising Phase 2 Results for ATH434 in MSA - GuruFocus